News & Updates

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

Treatment with resmetirom improves liver stiffness, fibrosis biomarkers, and risk scores for clinically significant portal hypertension (CSPH) in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis at 2 years, according to a study.

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

12 hours ago

Does long-term albumin therapy prolong survival in cirrhotic patients?

a day ago by

Long-term human albumin (LTA) therapy among cirrhotic patients with existing or prior ascites and acute decompensation results in improved transplant-free survival (TFS), mortality, and disease-related complications, according to the results of the PRECIOSA trial.

Does long-term albumin therapy prolong survival in cirrhotic patients?

a day ago

ACE-I/ARB use helps avert death in cirrhosis patients

13 May 2025

Exposure to angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent mortality among patients with cirrhosis, a study has shown.

ACE-I/ARB use helps avert death in cirrhosis patients

13 May 2025

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

Treatment with tenofovir alafenamide (TAF) is generally safe and effective for the prevention of hepatitis B virus (HBV) mother-to-child transmission (MTCT), reports a study, noting that the expected 8-week prenatal duration is feasible.

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

Another win for semaglutide: Improved outcomes in MASH with fibrosis

12 May 2025 by

Semaglutide may also confer hepatoprotective benefits, with interim efficacy data from the ongoing phase III ESSENCE study showing that the glucagon-like peptide-1 (GLP-1) receptor agonist helps dial down disease activity in patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate-to-severe fibrosis.

Another win for semaglutide: Improved outcomes in MASH with fibrosis

12 May 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

New drug applications approved by US FDA as of 1-15 April 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

SOF/VEL combo improves well-being of children with CHC

27 Apr 2025 by

In children with chronic hepatitis C (CHC), effective treatment with sofosbuvir/velpatasvir (SOF/VEL) results in improvements in certain areas of their well-being at 1 year. This suggests some patient-reported outcomes (PRO) benefits of direct-acting antiviral (DAA) therapy. However, the parents’ proxy reports show a decrease in the patients’ school functioning.

SOF/VEL combo improves well-being of children with CHC

27 Apr 2025

BPaL regimen tied to liver injury

10 Apr 2025

The overall risk of drug-induced liver injury (DILI) with the pretomanid, bedaquiline and linezolid (BPaL) regimen is lower compared with the isoniazid, rifampin, pyrazinamide and ethambutol (HRZE) regimen, a study has shown. However, the association between BPal and DILI remains significant, suggesting the need for careful monitoring during treatment.

BPaL regimen tied to liver injury

10 Apr 2025

Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B

01 Apr 2025 by

In the absence of infant hepatitis B immune globulin (HBIg), maternal tenofovir disoproxil fumarate (TDF) prophylaxis combined with infant hepatitis B virus (HBV) immunization provide sufficient protection against HBV infection in infants, findings from the iTAP-2 study suggest. However, the risk of infection was not demonstrably below 2 percent.

Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B

01 Apr 2025

Does plasma exchange improve survival in patients with acute liver failure?

27 Mar 2025

The use of therapeutic plasma exchange (PEX) in the management of acute liver failure (ALF) results in better haemodynamic parameters but offers no survival benefit, reports a study.

Does plasma exchange improve survival in patients with acute liver failure?

27 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

Resmetirom reduces liver stiffness, portal hypertension in MASH cirrhosis

Does long-term albumin therapy prolong survival in cirrhotic patients?

Does long-term albumin therapy prolong survival in cirrhotic patients?

ACE-I/ARB use helps avert death in cirrhosis patients

ACE-I/ARB use helps avert death in cirrhosis patients

TAF prophylaxis prevents mother-to-child transmission of HBV

TAF prophylaxis prevents mother-to-child transmission of HBV

Another win for semaglutide: Improved outcomes in MASH with fibrosis

Another win for semaglutide: Improved outcomes in MASH with fibrosis

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

SOF/VEL combo improves well-being of children with CHC

SOF/VEL combo improves well-being of children with CHC

BPaL regimen tied to liver injury

BPaL regimen tied to liver injury

Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B

Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B

Does plasma exchange improve survival in patients with acute liver failure?

Does plasma exchange improve survival in patients with acute liver failure?